Clinical Trials Logo

Autoantibodies clinical trials

View clinical trials related to Autoantibodies.

Filter by:
  • None
  • Page 1

NCT ID: NCT05867524 Recruiting - Interleukin-6 Clinical Trials

Characterization of Natural IL-6 Inhibition in Healthy Individuals

FIDI
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The aim of the project is to investigate whether or not there are any difference in cardiometabolic outcomes in individuals with high or low levels of c-aAb against interleukin-6 (IL-6). The study is the first to investigate individuals with extreme amounts of c-aAb levels against IL-6 and to contribute with knowledge on a possible new phenotype.

NCT ID: NCT04993885 Recruiting - Clinical trials for Immune Thrombocytopenia

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.

NCT ID: NCT04915482 Recruiting - Clinical trials for Connective Tissue Diseases

TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Start date: June 6, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This prospective, open-label, nonrandomized, multicenter clinical trial aims at comparing the efficacy and safety of combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody vs. the best available therapy(BAT)in adult immune thrombocytopenia with autoantibodies failed (due to intolerance or resistance) to first-line treatment.

NCT ID: NCT04192214 Completed - Heart Failure Clinical Trials

The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor

Start date: March 29, 2019
Phase: Phase 2
Study type: Interventional

Chronic heart failure (CHF) is one of the major causes of death in Western societies. Evidence has accumulated that functionally active autoantibodies directed against the beta1 adrenergic receptor (β1 AAb) are of pathophysiological relevance for the development and progression of cardiomyopathy and associated CHF. BC 007 is under development for targeted neutralisation of autoantibodies directed against G protein coupled receptors, including β1 AAb. This is an open label, three-centre, randomised phase 2a study in participants with chronic HFrEF. The study will evaluate whether BC 007 causes a persistent neutralisation of the β1 AAb demonstrated by a negative β1 AAb status up to 12 months. Participants will be randomised in a 2:1 ratio to the treatment arm (BC 007) or the control arm (untreated). Treatment is repeated once up to month 11 if the participant's β1 AAb were not neutralised after 1st dosing on day 1 or reoccur.

NCT ID: NCT02912442 Not yet recruiting - Infertility Clinical Trials

Thyroid Autoimmunity and Reproductive Failure in Danish Women

Start date: December 2016
Phase: N/A
Study type: Observational

The present Ph.D.-study investigates the mechanisms behind the association between thyroid autoimmunity and reproductive failure.